In our study, we saw trending increases in PD-L1 expression in non-immune tumor cells without the STAT1 binding site necessary for IFNγ, corroborating a recent study that found that IFN increased PD-L1 expression on liver cancer cells and required IFN-independent NAMPT [31]. The gene discussed is STAT1; the disease is liver cancer.